Tuberculosis (TB) remains one of the most important causes of death among people co-infected with human immunodeficiency virus (HIV). The diagnosis of TB remains challenging in HIV co-infected individuals, due to a high frequency of smear-negative disease and high rates of extrapulmonary TB. Accurate, ease of use and rapid diagnosis of active TB are critical to the World Health Organization (WHO) End TB Strategy by 2050. Traditional laboratory techniques do not provide rapid and accurate results to effectively manage HIV co-infected patients. Over the last decade, molecular methods have provided significant steps in the fight against TB. However, many HIV co-infected patients do not have access to these molecular diagnostic tests. Given the costs closely related with confirming a TB diagnosis in HIV patients, an overtreatment for TB is used in this patient population. Nowadays, an estimated US $8 billion a year is required to provide TB treatment, which is very high compared with making an important strategy to improve the current diagnostic tests. This review focuses on current advances in diagnosing active TB with an emphasis on the diagnosis of HIV-associated TB. Also discussed are the main challenges that need to be overcome for improving an adequate initial diagnosis of active TB in HIV-positive patients.
Introduction
Tuberculosis (TB) remains a major global public health problem with an estimated 10.4 million newly emerging active TB cases worldwide in 2016 [1] . Importantly, TB is the leading infectious cause of death in HIV co-infected patients [2, 3] . This is supported from a systematic review of autopsy studies of HIV-infected adults and children [4] [5] [6] , highlighting that diagnosis of TB in HIV co-infected individuals remains challenging for microbiologists. Methods available for the diagnosis of HIV-associated TB and recommended by the World Health Organization (WHO) include smear microscopy and mycobacterial culture [7, 8] . Although direct microscopy has the advantages of being a rapid and inexpensive test with high specificity for TB diagnosis, this method has poor sensitivity [9] . To date, molecular diagnostic tests have the technical capacity to overcome limitations of these conventional laboratory techniques [10] . In this regard, nucleic acid amplification tests (NAATs) developed to detect Mycobacterium tuberculosis (MTB)-complex nucleic acids, and urine lipoarabinomannan (LAM) lateral flow assay are used in a diagnosis of TB in HIV-infected patients [11, 12] . Indeed, given timely diagnosis is the first step in providing care to this patient population, new diagnostic tests are critical for timely initiation of anti-TB treatment. This review describes current progress in diagnosing active TB among HIV coinfected patients and identified some of the highest priorities for integration of new TB diagnostic tests into routine use.
inexpensive and rapid technique with high specificity for TB diagnosis in endemic areas. However, this technique has the limitation of low and variable sensitivity (20-60%) [13] . In this regard, fluorescent microscopy is more sensitive and allows a more rapid screening of large numbers of smears [14] . An important limitation of fluorescent microscopy is that this test is relatively expensive. However, the replacement of conventional fluorescent light sources with fluorescent light-emitting diode (LED) can significantly decrease cost [15] . Therefore, an important recommendation of the WHO for smear microscopy is the replacement of conventional fluorescent light sources with LED microscopy.
Mycobacterial culture
MTB culture on solid agar or in liquid culture remains as an important traditional test for diagnosis of TB. Solid culture is less expensive than liquid culture. However, liquid culture is faster and more sensitive [16] . Important advantages of this diagnostic test are the availability of strains for drug susceptibility testing (DST) and for genotyping to identify transmission events or outbreaks. Important limitations of mycobacterial culture are the need for infrastructure to support the appropriate biosafety level 3 laboratories and rapid transport of samples to the laboratory.
NAATs
NAATs have the potential to provide highly sensitive detection of paucibacillary forms of TB. At present, these molecular methods such as loop-mediated isothermal amplification test (LAMP) and Xpert MTB/RIF are playing an important role in the diagnosis of TB. These methods rely upon isothermal amplification or real-time polymerase chain reaction (PCR) techniques to rapidly identify the presence of MTB and mutations associated with rifampicin (RIF) resistance simultaneously.
Loop-mediated amplification test
The TB-loop-mediated isothermal amplification test assay (Eiken Chemical Co., Tokyo Japan) is the current NAAT temperature-independent method for amplifying DNA. An important advantage of this test is in terms of cost due to its result can be seen through a visual display that is easy to read [17] . In contrast, an important limitation of this test is that significant infrastructure requirements are necessary [18] . Interestingly, data from Yuan et al. [19] showed in a meta-analysis of 10 studies a sensitivity of 80% (78-83%) and specificity of 96% (95-97%) to diagnose pulmonary TB using LAMP in clinical samples. However, a study by Nliwasa et al. [20] reported that among HIV-associated patients a lower sensitivity of 65% (48-79%) was observed.
Xpert MTB/RIF
At present, Xpert MTB/RIF is the most widely adopted NAAT worldwide. The WHO endorsed Xpert MTB/RIF (Cepheid Inc, CA, USA), in December 2010 [21] . Xpert MTB/RIF assay is a cartridge-based real-time PCR automated system for rapid TB diagnosis and simultaneous identification of RIF resistance [22] [23] [24] . The WHO has recommended the use of this assay since 2013 as the initial diagnostic test in adults or children suspected of having HIV-associated TB or multidrug-resistant TB [25] . Important advantages of this test include simultaneous detection of RIF resistance, the limited training/expertise and relatively high sensitivity for smear-positive TB [26] . In contrast, limitations of this diagnostic test are that Xpert MTB/RIF does not distinguish between live and dead bacilli, it requires high-quality samples, is very highly priced in the private sector worldwide, and the clinical sensitivity with smear-negative specimens is only 67% reducing test impact [27] [28] [29] . In this regard, Scott et al. [30] showed that sensitivities were lower among smearnegative patients for diagnosing pulmonary TB on a single sputum specimen in South Africa. These data were supported by a publication from Theron et al. [31] which demonstrated that the sensitivity of Xpert MTB/RIF was good in smear-positive cases (95%), but was lower in smear-negative cases (55%) using liquid culture as the reference. In a latter publication, these authors demonstrated similar results using bronchoalveolar lavage fluid [32] . A more recent study reported that in smear-negative, culture-positive TB patients, Xpert MBT/RIF had a pooled sensitivity and specificity of 67% (range: 60%-75%) and 99% (range: 98%-99%), respectively [33] . The suboptimal sensitivity of sputum-based diagnostics using the Xpert MTB/RIF assay is due to the fact that this assay cannot be used to rule out TB in HIV-positive patients as a consequence to high rate of empiric TB treatment [34] [35] [36] . In addition, DNA co-extraction of PCR inhibitors from sputum may be at least in part, a cause of decreased test sensitivity. Importantly, strategies to improve sensitivity in TB diagnostic tests could be the use of DNA baits to extract M. tuberculosis DNA, the detection of multicopy targets, and the use of all of the extracted nucleic acid in the PCR detection of MTB [37] . Furthermore, using extrapulmonary samples sensitivity is highest for lymph node biopsies but lower for pleural fluid (Table 2 ) [38, 39] . Although the Xpert MTB/RIF assay is a method with known limitations, Albert et al. [40] have reviewed the impact of Xpert MTB/RIF, and reported that this assay it has become an important technique for the diagnosis of TB with RIF resistance. At present, Xpert HIV-1 Qualitative assay has been recommended by the WHO as an opportunity for integration of TB and HIV diagnosis [41] . This test would certainly be very useful to achieve the ambitious 90-90-90 targets: 90% of persons living with HIV must be diagnosed, 90% of those diagnosed should be on sustained therapy and 90% of those on therapy should have an undetectable viral load [42] . Patients can access the Xpert MTB/RIF test via the public sector and is available in several resource-poor and TB-endemic countries at concessional prices. At present, the Xpert MTB/RIF Assay is performed by purifying intact MTB from sputum, or by directly lysing MTB bacteria in sputum followed by extraction of DNA. As obtaining sputum samples may be very challenging, and the sample volume of sputum is generally limited [43] , there is an important interest in using non-pulmonary samples for the diagnosis of TB in HIV-infected patients. In this context, Lawn et al. [44] showed that although sputum Xpert MTB/RIF testing is more sensitive, urine Xpert MTB/RIF testing is able to diagnostic more cases of TB in HIV co-infected patients, indicating value of urine samples for diagnosis of TB in these individuals.
Urine lipoarabinomannan lateral flow assay
Other promising molecular TB diagnostic test is detection of structural MTB-specific molecules such as LAM, a component of the cell wall of MTB that may be found in urine of patients with active TB [45] . Urine LAM (Alere Inc., Waltham, MA, USA) assay is a urine-based antigen detection which can permit rapid initiation of therapy which contribute to reduction in mortality in HIV coinfected patients [46] . An important limitation of this diagnostic test is that the application of this method may be limited due to its lacks sensitivity for diagnosis of TB in HIV-uninfected patients. However, data from Peter et al. [47] indicated that the use of this method in high-burden countries can reduce early mortality at 8 weeks in hospitalized patients with severe immunodeficiency. Therefore, an important recommendation of the WHO for this method is its use for diagnosis of HIV-associated TB in patients whose CD4 cell counts is <100 cells/ll [48] , and advanced immunodeficiency [49] . Interestingly, a study from Shah et al. [50] reported that combining urine LAM assay with Xpert MTB/RIF testing of urine could be an important opportunity to improve the diagnosis of active TB in HIV co-infected patients, indicating an important use of urine as a specimen type for the diagnosis of HIVassociated TB.
Challenges and future directions for improving the diagnosis of active TB in HIV co-infected patients
Development of feasible, faster, and more sensitive molecular diagnostic tests to identify subclinical HIV co-infection is a good strategy to progress towards to end TB epidemic [51] [52] [53] . Despite the increasing use of new diagnostic tests for detection of TB has occurred in the past decade, current molecular diagnostic tests are not sufficiently rapid and accurate to manage HIV co-infected patients. In order to overcome this, the molecular technique Xpert MTB/RIF Ultra, a more sensitivity test due to additional multicopy DNA targets, and using a higher amount of extracted DNA, is currently under clinical evaluation [54] . An important advantage of this technique is that retains its ability to detect RIF resistance. Given the Xpert MTB/RIF assay can detect 5% to 15% of RIF-susceptible cases worldwide, a RIF-resistant Xpert MTB/RIF result can be confirmed with a different line probe assay (LPA). Nowadays, important research progress in the field of detection of multidrug resistance in MTB has been reported. In this regard, new multiplexed drug susceptibility assays have been used due to drug resistance in MTB occurs in several regions of the genome [55, 56] . At present, LPAs have been recommended for use by the WHO for the detection of RIF and isoniazid (INH) resistance in sputum smear-positive specimens and mycobacterial cultures [57] . These assays represent an important opportunity of reporting RIF and INH susceptibility simultaneously [58, 59] . A second-LPA used for the detection of resistance to anti-TB drugs includes probes to detect resistance to the class of fluoroquinolones drugs [60] , and the WHO recommended it use to detect resistance in patients diagnosed with resistance to RIF or for the diagnosis of extensively drug-resistant [61] . Another important molecular technology is the Abbott RealTime MTB RIF/INH resistance, an assay for the detection of RIF and INH resistant MTB in pulmonary specimens which is under evaluation [62] [63] [64] . The main limitations of these assays are that laboratory-trained staff in PCR, and appropriate laboratory infrastructure is required. It is important to consider that future evaluation studies will need a broader range of designs to determine the impact of these TB diagnostic tests on HIV co-infected patients [65] .
Other promising molecular techniques which in the future will impact a better TB diagnosis are based using the whole genome sequencing for MTB and next-generation sequencing [66] [67] [68] . The benefits of these diagnostic tests over current techniques for the diagnosis of active TB include a shorter time to diagnosis [69, 70] , to combine TB diagnosis and drug resistance profiling into one test [71] , to establish relapse or re-infection with MTB [72] , and a opportunity to identify whether there are the presence of mixed strain infection within the same patient [73, 74] . However, these new diagnostic tests of TB have some important challenges such as genomic DNA contains repeat elements which can be hundreds to thousands of base pairs in length, resulting in complete genomes [75, 76] . Also, another associated challenge is to determine whether differences between sequences occur because of sequence error or variance. To overcome this, multiple reads of the same sequence are required which can be compared to a reference dataset.
On the other hand, it may be appropriate in future development in diagnostic tests to have new biomarkers. At present, investment in biomarker research has increased. However, translation from biomarker discovery to clinical tools has been poor. In this regard, improved detection of the lipoglycan biomarker LAM could lead to a breakthrough in urine-based antigen detection [77] . Another approach to TB biomarkers is the analysis of mycobacteriaspecific lipid profiles. These lipids are known as mycobacterial lipidomics that can serve as diagnostic biomarkers. In this regard, Branch Moody et al. [78] reported progress in the lipidomic dissection of MTB. Interestingly, high concentrations of the lipidomic 1-tuberculosinyladenosine have been found in MTB, which have the potential to serve as a diagnostic target [79, 80] . More recently, ongoing research is focused on host transcriptional biomarkers, such as mRNA signatures for TB disease risk [81] [82] [83] . It is important to consider that new diagnostic tests for detection of TB must be optimized for the use of different specimen types including cerebrospinal fluid, lymph node, sputum, and urine. In fact, biomarkers measurable in the urine are of particular interest in the HIV-infected population, because they represent an easy, quick, and inexpensive method in diagnostic laboratory TB tests, and overcome the critical challenge to collect enough sputum samples for HIV patients with advanced immunodeficiency.
It may be necessary to emphasize that a major obstacle to the development of more sensitive diagnostic test for detection of MTB is the cost-effectiveness and resource implications of these methods, which must be optimized to each country [84] [85] [86] . In this context, the price will have to come down in the performance of molecular diagnostics for human TB in order that many HIV co-infected patients have access to these diagnostic tests. Nowadays, the TB diagnostics research has more than 50 diagnostic companies and product developers which are involved in developing new TB diagnostic technologies [87, 88] . However, they will require funding support to overcome important challenges, such as the cost of machines/ maintenance [89] . This funding support would be cheaper than US$1 billion which were spent worldwide on traditional TB diagnostics annually [90] , and would certainly be less than the annual global financial burden of TB treatment with an estimated of US$8 billion [91].
Conclusion
During the last decade, the use of new diagnostic tests for TB has increased significantly worldwide. In particular, new generation of molecular diagnostic tests has been used towards the integration of TB and HIV diagnosis.
However, most TB patients and/or vulnerable populations at increased risk of TB transmission still do not have access to the current diagnostic strategies. As an international health emergency, the TB epidemic requires interdisciplinary collaborative relationships among researchers across different countries to have a TB rational sequencing data platform. In addition, the next goal of the WHO Stop TB Strategy for TB elimination will require rapid diagnostic testing for active TB and drug susceptibility assays on MTB strains [92, 93] . In particular, highly sensitive assays capable of being performed on a range of specimen types are required to reduce reliance on empiric treatment and improve detection in highly vulnerable populations such as people living with HIV. In the meantime, increased investments are necessary to support the finding of new biomarkers and translation into clinical applications. In this regard, governments and/or philanthropic funders must work together to commit sustained funds towards the development of better and feasible TB diagnostic assays.
